Loading…
Theravance Biopharma, Inc. is projected to rise to $20.93 by 2027, a +23% move from its current price of $16.98. TBPH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $16.81 | $16.98 | $17.16 | +0.02% |
| Jul 13 | $16.74 | $16.99 | $17.24 | +0.04% |
| Jul 14 | $16.69 | $16.99 | $17.30 | +0.06% |
| Jul 15 | $16.64 | $16.99 | $17.35 | +0.08% |
| Jul 16 | $16.60 | $17.00 | $17.40 | +0.09% |
| Jul 17 | $16.57 | $17.00 | $17.44 | +0.11% |
| Jul 18 | $16.54 | $17.00 | $17.48 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.54 | $17.00 | $17.48 | +0.13% |
| Week 2 | $16.37 | $17.02 | $17.70 | +0.26% |
| Week 3 | $16.25 | $17.05 | $17.88 | +0.40% |
| Week 4 | $16.15 | $17.07 | $18.04 | +0.53% |
| Week 5 | $16.07 | $17.09 | $18.18 | +0.66% |
| Week 6 | $15.99 | $17.11 | $18.31 | +0.79% |
| Week 7 | $15.93 | $17.14 | $18.44 | +0.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Theravance Biopharma, Inc. is a biopharmaceutical company that develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor, which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc.
was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc. (TBPH) is currently priced at $16.58. Its market capitalization is $854.75M and it is ranked 2659. The stock shows a bullish long‑term forecast with the average price rising over the years: 2026 avg $16.58, 2030 avg $36.19, 2040 avg $91.10, and 2050 avg $215.84, with ROIs of 118.3% in 2030, 449.5% in 2040, and 1201.8% in 2050.
The near‑term 30‑day range is $15.36 to $17.89, reflecting a tight corridor around the current level.
A major floor 20.1% below — a decisive break under it would weaken the trend.
The nearest floor, 8.2% below — buyers have tended to step in here.
The nearest ceiling, 3.8% above — a clean break opens room to run.
A major ceiling 10.5% above — clearing it would confirm fresh momentum.
Key TBPH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TBPH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.98 | Sell | $16.98 | Buy |
| MA 10 | $17.05 | Sell | $16.98 | Buy |
| MA 20 | $16.91 | Buy | $16.88 | Buy |
| MA 50 | $16.63 | Buy | $16.70 | Buy |
| MA 100 | $16.36 | Buy | $16.65 | Buy |
| MA 200 | $16.86 | Buy | $16.03 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.23 | Neutral |
| Stoch RSI (14) | 0.22 | Buy |
| CCI (20) | 6.50 | Neutral |
| Williams %R (14) | -65.42 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -0.24 | Sell |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 34.58 | Neutral |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | 0.37 | Buy |
| Ultimate (7,14,28) | 45.18 | Neutral |
| Momentum (10) | -0.46 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 16.97 | Buy |
| ADX (14) | 12.63 | Neutral |
| ATR (14) | 0.14 | Info |
The 30‑day technical picture is bullish. RSI14 is 50, with the short‑term moving averages near the current price: SMA50 at $16.51 and SMA200 at $16.64. Support sits at $15.58 and resistance at $17.02, defining a near‑term boundary. The 30‑day range runs from $15.36 to $17.89, illustrating the price band for the coming weeks. Annualized volatility is 20%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.57 | $16.98 | $22.59 | 0% | Neutral | |
| $17.14 | $20.93 | $26.72 | +23% | Bullish | |
| $20.54 | $25.55 | $33.49 | +50% | Bullish | |
| $25.58 | $32.31 | $43.26 | +90% | Bullish | |
| $29.25 | $37.45 | $51.04 | +121% | Bullish | |
| $33.62 | $43.56 | $60.32 | +157% | Bullish | |
| $34.74 | $45.53 | $63.94 | +168% | Bullish | |
| $36.38 | $48.18 | $68.54 | +184% | Bullish | |
| $43.39 | $58.04 | $83.55 | +242% | Bullish | |
| $49.20 | $66.42 | $96.68 | +291% | Bullish | |
| $71.94 | $101.30 | $154.53 | +497% | Bullish | |
| $159.09 | $240.26 | $392.85 | +13.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $13.57 | $16.98 | $20.47 | +0.00% |
| August 2026 | $14.76 | $17.28 | $20.67 | +1.79% |
| September 2026 | $14.68 | $17.27 | $20.82 | -0.06% |
| October 2026 | $15.19 | $17.95 | $21.78 | +3.90% |
| November 2026 | $15.59 | $18.47 | $22.54 | +2.93% |
| December 2026 | $15.50 | $18.43 | $22.59 | -0.26% |
Click any year to see its month-by-month TBPH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TBPH is projected to trade between $13.57 and $22.59, averaging $16.98 — a potential gain of 0% from today's $16.98. A consolidation phase looks the most probable path here.
Theravance Biopharma, Inc.'s 2027 outlook centres on $20.93, within a $17.14 to $26.72 range. That is up +23% on the projected 2026 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2028, TBPH could reach as high as $33.49, with a base case around $25.55 and support toward $20.54 — roughly +50% from $16.98. Buyers look set to stay in control over this stretch.
Expect TBPH to range from $25.58 to $43.26 through 2029. The $32.31 average target implies a +90% move from current prices. That is up +26% on the projected 2028 average. Momentum favours further upside here.
The TBPH price prediction for 2030 points to an average of $37.45 (low $29.25, high $51.04) — a potential gain of +121% on today's $16.98. Buyers look set to stay in control over this stretch.
In 2031, TBPH is projected to trade between $33.62 and $60.32, averaging $43.56 — a potential gain of +157% from today's $16.98. That is up +16% on the projected 2030 average. Momentum favours further upside here.
Theravance Biopharma, Inc.'s 2032 outlook centres on $45.53, within a $34.74 to $63.94 range. That is up +5% on the projected 2031 average. That marks a +168% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TBPH could reach as high as $68.54, with a base case around $48.18 and support toward $36.38 — roughly +184% from $16.98. Momentum favours further upside here.
Expect TBPH to range from $43.39 to $83.55 through 2034. The $58.04 average target implies a +242% move from current prices. That is up +20% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TBPH price prediction for 2035 points to an average of $66.42 (low $49.20, high $96.68) — a potential gain of +291% on today's $16.98. Momentum favours further upside here.
In 2040, TBPH is projected to trade between $71.94 and $154.53, averaging $101.30 — a potential gain of +497% from today's $16.98. That is up +53% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Theravance Biopharma, Inc.'s 2050 outlook centres on $240.26, within a $159.09 to $392.85 range. That is up +137% on the projected 2040 average. That marks a +13.1x change versus current levels. Momentum favours further upside here.
Investing $1,000 in TBPH today (≈ 58.892815 TBPH) could be worth
$14,149.52
+$13,149.52 (+1315%) by 2050 · US Dollar
Based on the average projected TBPH price of $240.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TBPHwould be worth at today's price.
$1,000 invested in TBPH on Jul 10, 2025 (≈ 87.260035 TBPH) would be worth
$1,481.68
+$481.68 (+48.2%) today · 1.48× · US Dollar
Based on a TBPH entry price of $11.46 vs. today's $16.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.93 | $1,002.95 | +0.3% |
| 1 month ago | $16.37 | $1,037.26 | +3.7% |
| 3 months ago | $16.35 | $1,038.53 | +3.9% |
| 6 months ago | $19.65 | $864.12 | -13.6% |
| 1 year ago | $11.46 | $1,481.68 | +48.2% |
| All time (5.0y) ago | $14.02 | $1,211.13 | +21.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TBPH forecast.
Our base-case forecast reaches $34.00 around 2030.
Implied market cap at $34.00: $1.76B
The multi‑year forecast shows a bullish trajectory, with the average price rising from $16.58 in 2026 to $36.19 in 2030, $91.10 in 2040, and $215.84 in 2050. Corresponding ROIs are 118.3% in 2030, 449.5% in 2040, and 1201.8% in 2050. Nearer years show continued upside, with 2027 avg $20.64, 2028 avg $24.18, and 2029 avg $30.91, culminating in 2050’s strong long‑term outlook.
Sentiment remains BULLISH across the forecast, but these are estimates, not guarantees, andvolve with market conditions and volatility.
Tap a question to reveal the answer.
The 2030 avg price is $36.19, with a min of $28.25 and a max of $49.38; ROI 118.3%. Sentiment is BULLISH.
The forecast shows a bullish sentiment across multiple years, with avg prices rising from $16.58 in 2026 to $215.84 by 2050. ROIs reach 24.5% in 2027, 45.9% in 2028, 86.4% in 2029, 118.3% in 2030, 143.4% in 2031, 156.2% in 2032, 175.9% in 2033, 222.3% in 2034, 269.8% in 2035, 449.5% in 2040, and 1201.8% in 2050. Sentiment is bullish overall, but these are estimates and not guarantees.
The 2030 max is $49.38, which is below 50, but the 2031 max is $55.92 and the 2034 max is $76.98, indicating that beyond 2030 the $50 level is reachable per the forecast.
Current price $16.58; Market cap $854.75M; Rank 2659.
The 2050 avg price is $215.84, with a min of $142.87 and a max of $353.04; ROI 1201.8%. Sentiment is BULLISH.
Theravance Biopharma, Inc. Community Discussion
0Share your Theravance Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.